Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545

Transplantation

Volumn 94, Issue 7, 2012, Pages 695-702

  Deuse, Tobias ^a,b   Hua, Xiaoqin ^a,b   Taylor, Vanessa ^c   Stubbendorff, Mandy ^a,b   Baluom, Muhammad ^c   Chen, Yan ^c   Park, Gary ^c   Velden, Joachim ^d   Streichert, Thomas ^d   Reichenspurner, Hermann ^a,b   Robbins, Robert C ^e   Schrepfer, Sonja ^a,b,e  

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c RIGEL PHARMACEUTICALS INC   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute cardiac allograft rejection; JAK1 3 inhibitor; Novel immunosuppression

Indexed keywords

ALPHA INTERFERON; ERYTHROPOIETIN; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; R 369; R 507; R 545; TACROLIMUS; TOFACITINIB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME RELEASE; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 TH2 BALANCE;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; JANUS KINASE 1; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MYOCARDIUM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED BN; RATS, INBRED LEW; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TACROLIMUS;

EID: 84867249464     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182660496     Document Type: Article

References (55)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twentyseventh official adult heart transplant reportV2010. J Heart Lung Transplant 2010; 29: 1089.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004: 351: 2715.
3. Wang S, Guan Q, Diao H, et al. Prolongation of cardiac allograft survival by inhibition of ERK1/2 signaling in a mouse model. Transplantation 2007; 83: 323.
4. Haidinger M, Werzowa J, Weichhart T, et al. Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone. Transplant Rev (Orlando) 2011; 25: 145.
5. Li J, Chen G, Ye P, et al. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 2011; 186: 3753.
6. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8: 1972.
7. Hoitsma AJ, Woodle ES, Abramowicz D, et al. FTY720 Phase II Transplant Study Group. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant 2011; 26: 3802.
8. Guasch A, Roy-Chaudhury P, Woodle ES, et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 2010; 90: 891.
9. Zeng H, Waldman WJ, Yin DP, et al. Mechanistic study of malononitrileamide FK778 in cardiac transplantation and CMV infection in rats. Transplantation 2005; 79: 17.
10. Pan S, Mi Y, Pally C, et al. A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol 2006; 13: 1227.
11. O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555.
12. Higuchi T, Shiraishi T, Shirakusa T, et al. Prevention of acute lung allograft rejection in rat by the janus kinase 3 inhibitor, tyrphostin AG490. J Heart Lung Transplant 2005; 24: 1557.
13. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005; 79: 791.
14. Wang LH, Kirken RA, Erwin RA, et al. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2Ymediated T cell response. J Immunol 1999; 162: 3897.
15. Behbod F, Erwin-Cohen RA, Wang ME, et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 2001; 166: 3724.
16. Stepkowski SM, Nagy ZS, Wang ME, et al. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc 2001; 33: 3272.
17. Velotta JB, Deuse T, Haddad M, et al. A novel JAK3 inhibitor, R348, attenuates chronic airway allograft rejection. Transplantation 2009; 87: 653.
18. Deuse T, Velotta JB, Hoyt G, et al. Novel immunosuppression: R348, a JAK3-and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008; 85: 885.
19. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
20. Kahan BD. Frontiers in immunosuppression. Transplant Proc 2011; 43: 822.
21. Gaffen SL. Signaling domains of the interleukin 2 receptor. Cytokine 2001; 14: 63.
22. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994; 370: 151.
23. Johnston JA, Bacon CM, Riedy MC, et al. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency. J Leukoc Biol 1996; 60: 441.
24. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373.
25. Thomis DC, Gurniak CB, Tivol E, et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270: 794.
26. Notarangelo LD, Giliani S, Mella P, et al. Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology 2000; 202: 106.
27. O'Shea JJ, Husa M, Li D, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004; 41: 727.
28. Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18: 314.
29. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385.
30. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998; 93: 397.
31. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669.
32. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008; 111: 5663.
33. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291: H827.
34. Baker JE, Su J, Hsu A, et al. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 2008; 77: 44.
35. Smith CC, Dixon RA, Wynne AM, et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010; 299: H1265.
36. Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cellY stimulated T cells yet preserves immunity to recall antigen. Blood 2011; 118: 5330.
37. Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and-gamma signal transduction. Nature 1993; 366: 129.
38. Busque S, Leventhal J, Brennan DC, et al. Calcineurin-inhibitorYfree immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant 2009; 9: 1936.
39. Vincenti F, Tedesco Silva H, Busque S, et al. A phase 2B study of CNIfree immunosuppression with the JAK inhibitor CP-690,550 in de novo kidney transplant patients: 6-month interim analysis. Am J Transplant 2010; 10: 211.
40. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127.
41. Li C, Kraemer FB, Ahlborn TE, et al. Induction of low density lipoprotein receptor (LDLR) transcription by oncostatinMis mediated by the extracellular signalYregulated kinase signaling pathway and the repeat 3 element of the LDLR promoter. J Biol Chem 1999; 274: 6747.
42. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513.
43. Paniagua R, Si MS, Flores MG, et al. Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts. Transplantation 2005; 80: 1283.
44. Tanimoto A, Murata Y, Wang KY, et al. Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colonystimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells. J Biol Chem 2008; 283: 4643.
45. Wei L, Laurence A, O'Shea JJ. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 2008; 19: 394.
46. Pallandre JR, Brillard E, Crehange G, et al. Role of STAT3 in CD4+ CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol 2007; 179: 7593.
47. Heidt S, Segundo DS, Chadha R, et al. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010; 15: 456.
48. Booth AJ, Bishop DK. TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2010; 2: 511.
49. Wang S, Li J, Xie A, et al. Dynamic changes in Th1, Th17, and FoxP3+ T cells in patients with acute cellular rejection after cardiac transplantation. Clin Transplant 2011; 25: E177.
50. Celik S, Doesch AO, Konstandin MH, et al. Increased incidence of acute graft rejection on calcineurin inhibitorYfree immunosuppression after heart transplantation. Transplant Proc 2011; 43: 1862.
51. Changelian PS, FlanaganME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875.
52. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
53. Chou T. The median-effect principle and combination index for quantitation of synergism. In: Chou TC RD, ed. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press; 1991: 61.
54. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710.
55. Schrepfer S, Deuse T, Koch-Nolte F, et al. FK778 in experimental xenotransplantation: a detailed analysis of drug efficacy. J Heart Lung Transplant 2007; 26: 70.